Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report

DOI: 10.1159/000501848

Keywords: Afatinib, EGFR uncommon mutation, Immune-checkpoint inhibitor, Non-small-cell lung cancer, Pembrolizumab

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text